Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experienceReport as inadecuate




Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience - Download this document for free, or read online. Document in PDF available to download.

Italian Journal of Pediatrics

, 43:40

First Online: 19 April 2017Received: 17 January 2017Accepted: 08 April 2017DOI: 10.1186-s13052-017-0357-9

Cite this article as: El Hachem, M., Gesualdo, F., Diociaiuti, A. et al. Ital J Pediatr 2017 43: 40. doi:10.1186-s13052-017-0357-9

Abstract

BackgroundDespite not being licensed for the treatment of infantile hemangiomas IH in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications. The objective of the present study was to review the experience of 8 Italian pediatric and dermatologic centers regarding propranolol treatment for IH started before 5 weeks or after 5 months of age.

MethodsWe retrospectively reviewed the records of patients followed up for IH, on propranolol treatment started before 5 weeks or after 5 months of age, and collected information on sociodemographic data, treatment indications, IH involution, IH relapse, and treatment side effects.

ResultsA total of 343 patients were enrolled; 15 were started on propranolol before 5 weeks group 1, 328 were started after 5 months of age group 2. The most frequent indications were permanent aesthetical disfigurement 91.8% and function threatening complications 42.6%.

In most cases, the treatment was effective. The involution was partial in 67.7% of patients. In 11.8% of cases a relapse was observed. No relapse was observed in group 1. Treatment complications were reported in 15.8% of children, most frequently sleep disorders 6.6%, followed by irritability 5.1% and diarrhea 2.2%. Only a case of mild constipation was observed in group 1.

ConclusionThe safety and effectiveness profile of propranolol in infants younger than 5 weeks or older than 5 months may be acceptable. Taking in account propranolol-s potential in preventing severe complications, further studies should assess the acceptability of propranolol treatment, especially in the <5-week age group .





Author: Maya El Hachem - Francesco Gesualdo - Andrea Diociaiuti - Irene Berti - Nadia Vercellino - Valeria Boccaletti - Iria Neri -

Source: https://link.springer.com/







Related documents